Steroid myopathy in dogs

In AFCAPS/TexCAPS, the number of participants with consecutive elevations of either alanine aminotransferase (ALT) or aspartate aminotransferase (AST) (> 3 times the upper limit of normal), over a median of years of follow-up, was not significantly different between the Lovastatin and placebo groups (18 [%] vs. 11 [%]). The starting dose of Lovastatin was 20 mg/day; 50% of the Lovastatin treated participants were titrated to 40 mg/day at Week 18. Of the 18 participants on Lovastatin with consecutive elevations of either ALT or AST, 11 (%) elevations occurred in participants taking 20 mg/day, while 7 (%) elevations occurred in participants titrated to 40 mg/day. Elevated transaminases resulted in discontinuation of 6 (%) participants from therapy in the Lovastatin group (n=3,304) and 4 (%) in the placebo group (n=3,301).

Steroid myopathy in dogs

steroid myopathy in dogs

Media:

steroid myopathy in dogssteroid myopathy in dogssteroid myopathy in dogssteroid myopathy in dogs